Topic: Policy: Value Assessment and International Reference Pricing

Special Assessment to Inform CMS Drug Price Negotiation: Eliquis and Xarelto

Oct 2023 | Policy Paper

ICER is developing a special report evaluating the evidence on apixaban (Eliquis®, Bristol Myers Squibb) and rivaroxaban (Xarelto®, Bayer) for the treatment of nonvalvular atrial fibrillation (NVAF). ICER plans to release this report in September 2023 and submit it to the Centers for Medicare and Medicaid Services (CMS) as part of the public comment process […]

Value Assessment and International Reference Pricing

Sep 2021 | Policy Paper

The need to improve drug affordability remains one of the few areas of bipartisan agreementin the US, with polling showing that a majority of both Democrats and Republicans want thefederal government to act to lower prescription drug prices. Policymakers from both partieshave advanced proposals to rein in drug costs, but there is no consensus on […]